WNDM Medical Inc (WNDM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:WNDM Medical Inc (WNDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8036
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
WNDM Medical Inc (WNDM Medical), formerly Wound Management Technologies Inc is a distributor of biotechnology products to hospitals, physicians, and clinics. The company offers its patented product CellerateRX in powder and gel forms, and hemaquell resorbable bone wax that controls bone bleeding. Its product finds application in all except third degree burns, acute wounds, and chronic wounds. WNDM Medical discovers, develops, and markets advanced wound care products. The company has license agreement with Applied Nutritional for patented technologies and processes related to CellerateRX. It markets its products through independent distributors, healthcare distributors, distributor organizations, and sales representatives. WNDM Medical is headquartered in Fort Worth, Texas, the US.

WNDM Medical Inc (WNDM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WNDM Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
WNDM Medical Inc, Medical Devices Deals, 2012 to YTD 2018 9
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Wound Management Technologies Raises USD0.2 Million in Rights Offering of Shares 11
Wound Management Technologies Announces Private Placement Of Shares For US$2.4 Million 12
Debt Offering 13
Wound Management Technologies Raises USD0.5 Million in Private Placement of 10% Notes 13
Wound Management Technologies Raises USD0.4 Million in Public Offering of Debentures Due 2015 14
WNDM Medical Inc – Key Competitors 15
WNDM Medical Inc – Key Employees 16
WNDM Medical Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 19
Financial Announcements 19
Jul 12, 2018: WNDM Medical Announces Record Sales for the Second Quarter of 2018 – Up 56% over Second Quarter 2017 19
Mar 29, 2018: Wound Management Technologies Announces Record Annual Sales Ending December 31, 2017 – Up 14% over 2016 20
Jul 20, 2017: Wound Management Technologies Announces Q2 2017 Sales Up 15% over Q2 2016 and All Amortized Debt Retired in the Second Quarter 21
May 17, 2017: Wound Management Issues 2017 10Q and Hires New Strategic Marketing Director 22
Apr 27, 2017: Q1 2017 Sales Up 32% Over Q1 2016, for Wound Management Technologies 23
Feb 14, 2017: Wound Management Technologies Announces Record Quarterly and Annual Sales Ending December 31, 2016 – Up 147% over Q4 2015, and 63% over 2015 24
Corporate Communications 25
Feb 15, 2018: Wound Management Technologies Announces J. Michael Carmena Appointed Chief Executive Officer 25
Mar 08, 2017: Wound Management announces appointment of John Siedhoff as Chairman 26
Other Significant Developments 27
Apr 03, 2018: Wound Management Technologies Changes Name to WNDM Medical 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
WNDM Medical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WNDM Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WNDM Medical Inc, Deals By Therapy Area, 2012 to YTD 2018 8
WNDM Medical Inc, Medical Devices Deals, 2012 to YTD 2018 9
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Wound Management Technologies Raises USD0.2 Million in Rights Offering of Shares 11
Wound Management Technologies Announces Private Placement Of Shares For US$2.4 Million 12
Wound Management Technologies Raises USD0.5 Million in Private Placement of 10% Notes 13
Wound Management Technologies Raises USD0.4 Million in Public Offering of Debentures Due 2015 14
WNDM Medical Inc, Key Competitors 15
WNDM Medical Inc, Key Employees 16
WNDM Medical Inc, Subsidiaries 17
WNDM Medical Inc, Joint Venture 17

List of Figures
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
WNDM Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
WNDM Medical Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[WNDM Medical Inc (WNDM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Neuralstem, Inc. (CUR):企業概要、財務及び戦略的SWOT分析
    Summary Neuralstem, Inc. (Neuralstem) is a pharmaceutical company. The company develops and markets medicines based on human neural stem cell technology and cell therapy. It provides cell therapy treatment for ALS, ischemic stroke, spinal cord injury, glioblastoma, multiple sclerosis, optic neuritis …
  • Collegium Pharmaceutical, Inc. (COLL):企業のM&A・提携動向(医療機器分野)
    Summary Collegium Pharmaceutical, Inc. (Collegium) is a specialty pharmaceutical company, which develops products for the treatment of chronic pain that incorporate its DETERx oral drug delivery technology. Collegium’s lead candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formula …
  • Zenrin Co., Ltd. (9474):企業財務及び戦略的SWOT分析
    Summary Zenrin Co., Ltd. (Zenrin) is a technology company that offers premium mapping products and services. The company provides map software, in-car navigation software and related IT services for various purposes. Its products include residential maps, digital maps, special purpose maps. Zenrin’s …
  • Trimble Navigation Limited:企業の戦略・SWOT・財務分析
    SummaryTrimble Navigation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. …
  • Gujarat NRE Coke Limited (GUJNRECOKE):企業の財務及び戦略的SWOT分析
    Summary Gujarat NRE Coke Limited (GNCL) is a coke manufacturer that produces low ash metallurgical coke. The company offers products such as met coke, electric power and TMT bars. It generates electricity from wind power projects and cogeneration power plants. GNCL offers services such as recycling …
  • Bourbon Corporation:企業の戦略・SWOT・財務分析
    SummaryBourbon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fin …
  • Alfa Wassermann SpA:企業のM&A・提携動向(医療分野)
    Summary Alfa Wassermann SpA (Alfa Wassermann) is a pharmaceutical company that research, produces and distributes drugs for human health. The company offers new discoveries in medicine, biology and genomics. It provides self-medication products for treatment of sore throat, headaches, and muscle and …
  • Vietnam Dairy Products Joint Stock Co:戦略・SWOT・企業財務分析
    Vietnam Dairy Products Joint Stock Co - Strategy, SWOT and Corporate Finance Report Summary Vietnam Dairy Products Joint Stock Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Per Aarsleff A/S:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Per Aarsleff A/S" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. World Market Intelligence …
  • Imbed Biosciences, Inc.:企業のM&A・提携動向(医療機器分野)
    Summary Imbed Biosciences, Inc. (Imbed) is a medical device company that provides novel advanced materials for wound healing and surgical applications. The company’s product platform includes antibacterial wound dressings, antibiofilm wound dressings and analgesic wound dressings. Its antibacterial …
  • Stirling Products Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Stirling Products Limited Merge …
  • Lepu Medical Technology (Beijing) Co., Ltd. (300003):企業のM&A・提携動向(医療機器分野)
    Summary Lepu Medical Technology (Beijing) Co., Ltd. (Lepu Medical) is a medical device company that designs, develops, manufactures, markets and distributes medical equipment for the healthcare market. The company offers interventional cardiology products, critical care products, anesthetic products …
  • Proserv:石油・ガス:M&Aディール及び事業提携情報
    Summary Proserv is an energy service provider that offers engineering services. The company offers drilling, surface, subsea and decommissioning services. Its subsea services comprise subsea engineering, subsea production equipment and services, subsea components and accessories, subsea production e …
  • Palmaz Scientific, Inc.:(医療機器分野)企業M&A及び提携動向
    Summary Palmaz Scientific, Inc. (Palmaz) develops and manufactures implantable prosthetic devices. It uses nanotechnology platform for producing implantable devices. Palmaz offers metal micromesh thin film coverings for stents, micro-neuro and vascular stents, angioplasty balloons, drug delivery dev …
  • Patrick Industries, Inc.:企業のM&A・提携・投資分析
    Patrick Industries, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Patrick Industries, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • AmerisourceBergen Corporation:企業の戦略・SWOT・財務分析
    AmerisourceBergen Corporation - Strategy, SWOT and Corporate Finance Report Summary AmerisourceBergen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • SonarMed Inc:医療機器:M&Aディール及び事業提携情報
    Summary SonarMed Inc (SonarMed) is a medical device company that develops endotrachael systems used for the inhalation and ventilation assistance patients. The company offers products such as artificial respiratory, endotrachael tubes, biomedical acoustics, SonarMed Airwave, medical devices, disposa …
  • Lloyds TSB Bank plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Lloyds TSB Bank plc Mergers and …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務及び戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a pharmaceutical company that develops and markets animal healthcare products. The company offers products such as Alvegesic vet, Canaural, Cardisure, Comfortan, Cyclospray, Eclypse, Equipalazone, Felimazole, Fuciderm, Lignol, Lubrel, Malaseb, Methoxaso …
  • China Aerospace Science and Technology Corporation:企業の戦略・SWOT・財務情報
    China Aerospace Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary China Aerospace Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆